Back to Search Start Over

Cre-inducible human CD59 mediates rapid cell ablation after intermedilysin administration.

Authors :
Feng D
Dai S
Liu F
Ohtake Y
Zhou Z
Wang H
Zhang Y
Kearns A
Peng X
Zhu F
Hayat U
Li M
He Y
Xu M
Zhao C
Cheng M
Zhang L
Wang H
Yang X
Ju C
Bryda EC
Gordon J
Khalili K
Hu W
Li S
Qin X
Gao B
Source :
The Journal of clinical investigation [J Clin Invest] 2016 Jun 01; Vol. 126 (6), pp. 2321-33. Date of Electronic Publication: 2016 May 09.
Publication Year :
2016

Abstract

Cell ablation is a powerful tool for studying cell lineage and/or function; however, current cell-ablation models have limitations. Intermedilysin (ILY), a cytolytic pore-forming toxin that is secreted by Streptococcus intermedius, lyses human cells exclusively by binding to the human complement regulator CD59 (hCD59), but does not react with CD59 from nonprimates. Here, we took advantage of this feature of ILY and developed a model of conditional and targeted cell ablation by generating floxed STOP-CD59 knockin mice (ihCD59), in which expression of human CD59 only occurs after Cre-mediated recombination. The administration of ILY to ihCD59+ mice crossed with various Cre-driver lines resulted in the rapid and specific ablation of immune, epithelial, or neural cells without off-target effects. ILY had a large pharmacological window, which allowed us to perform dose-dependent studies. Finally, the ILY/ihCD59-mediated cell-ablation method was tested in several disease models to study immune cell functionalities, hepatocyte and/or biliary epithelial damage and regeneration, and neural cell damage. Together, the results of this study demonstrate the utility of the ihCD59 mouse model for studying the effects of cell ablation in specific organ systems in a variety of developmental and disease states.

Details

Language :
English
ISSN :
1558-8238
Volume :
126
Issue :
6
Database :
MEDLINE
Journal :
The Journal of clinical investigation
Publication Type :
Academic Journal
Accession number :
27159394
Full Text :
https://doi.org/10.1172/JCI84921